The combination of venetoclax, daratumumab and dexamethasone for the treatment of refractory primary plasma cell leukemia

被引:26
作者
Nalghranyan, Sos [1 ]
Singh, Amrit P. [2 ]
Schinke, Carolina [1 ]
机构
[1] Univ Arkansas Med Sci, Myeloma Ctr, Winthrop P Rockefeller Canc Inst, Little Rock, AR 72205 USA
[2] Univ Arkansas Med Sci, Dept Pathol, Little Rock, AR 72205 USA
关键词
D O I
10.1002/ajh.25676
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
引用
收藏
页码:E34 / E35
页数:2
相关论文
共 6 条
[1]   Combination therapy incorporating Bcl-2 inhibition with Venetoclax for the treatment of refractory primary plasma cell leukemia with t (11;14) [J].
Gonsalves, Wilson I. ;
Buadi, Francis K. ;
Kumar, Shaji K. .
EUROPEAN JOURNAL OF HAEMATOLOGY, 2018, 100 (02) :215-217
[2]   Single-agent venetoclax induces MRD-negative response in relapsed primary plasma cell leukemia with t(11;14) [J].
Jelinek, Tomas ;
Mihalyova, Jana ;
Kascak, Michal ;
Duras, Juraj ;
Popkova, Tereza ;
Benkova, Katerina ;
Richterova, Petra ;
Plonkova, Hana ;
Zuchnicka, Jana ;
Broskevicova, Lucie ;
Huvarova, Lucie ;
Cerna, Lucie ;
Growkova, Katerina ;
Simicek, Michal ;
Havel, Martin ;
Gumulec, Jaromir ;
Navratil, Milan ;
Koristek, Zdenek ;
Paiva, Bruno ;
Hajek, Roman .
AMERICAN JOURNAL OF HEMATOLOGY, 2019, 94 (01) :E35-E37
[3]   The prognostic value of the depth of response in multiple myeloma depends on the time of assessment, risk status and molecular subtype [J].
Schinke, Carolina ;
Hoering, Antje ;
Wang, Hongwei ;
Carlton, Victoria ;
Thanandrarajan, Sharmilan ;
Deshpande, Shayu ;
Patel, Purvi ;
Molnar, Gabor ;
Susanibar, Sandra ;
Mohan, Meera ;
Mathur, Pankaj ;
Radhakrishnan, Muthukumar ;
Hoque, Shadiqul ;
Kamimoto, Jorge Jo ;
Grazziutti, Monica ;
van Rhee, Frits ;
Zangari, Maurizio ;
Insuasti-Beltran, Giovanni ;
Alapat, Daisy ;
Post, Ginell ;
Yaccoby, Shmuel ;
Epstein, Joshua ;
Rasche, Leo ;
Johnson, Sarah ;
Moorhead, Martin ;
Willis, Tom ;
Barlogie, Bart ;
Walker, Brian ;
Weinhold, Niels ;
Davies, Faith E. ;
Morgan, Gareth J. .
HAEMATOLOGICA, 2017, 102 (08) :E313-E316
[4]   Targeting Bcl-2 for the treatment of multiple myeloma [J].
Touzeau, Cyrille ;
Maciag, Paulo ;
Amiot, Martine ;
Moreau, Philippe .
LEUKEMIA, 2018, 32 (09) :1899-1907
[5]   Primary plasma cell leukemia: clinical and laboratory presentation, gene-expression profiling and clinical outcome with Total Therapy protocols [J].
Usmani, S. Z. ;
Nair, B. ;
Qu, P. ;
Hansen, E. ;
Zhang, Q. ;
Petty, N. ;
Waheed, S. ;
Shaughnessy, J. D., Jr. ;
Alsayed, Y. ;
Heuck, C. J. ;
Van Rhee, F. ;
Milner, T. ;
Hoering, A. ;
Szymonifka, J. ;
Sexton, R. ;
Sawyer, J. ;
Singh, Z. ;
Crowley, J. ;
Barlogie, B. .
LEUKEMIA, 2012, 26 (11) :2398-2405
[6]   A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis [J].
Walker, Brian A. ;
Mavrommatis, Konstantinos ;
Wardell, Christopher P. ;
Ashby, T. Cody ;
Bauer, Michael ;
Davies, Faith ;
Rosenthal, Adam ;
Wang, Hongwei ;
Qu, Pingping ;
Hoering, Antje ;
Samur, Mehmet ;
Towfic, Fadi ;
Ortiz, Maria ;
Flynt, Erin ;
Yu, Zhinuan ;
Yang, Zhihong ;
Rozelle, Dan ;
Obenauer, John ;
Trotter, Matthew ;
Auclair, Daniel ;
Keats, Jonathan ;
Bolli, Niccolo ;
Fulciniti, Mariateresa ;
Szalat, Raphael ;
Moreau, Phillipe ;
Durie, Brian ;
Stewart, A. Keith ;
Goldschmidt, Hartmut ;
Raab, Marc S. ;
Einsele, Hermann ;
Sonneveld, Pieter ;
San Miguel, Jesus ;
Lonial, Sagar ;
Jackson, Graham H. ;
Anderson, Kenneth C. ;
Avet-Loiseau, Herve ;
Munshi, Nikhil ;
Thakurta, Anjan ;
Morgan, Gareth .
LEUKEMIA, 2019, 33 (01) :159-170